20
Views
12
CrossRef citations to date
0
Altmetric
Articles

Potential Transmission of the Cytogenetic Effects of Cisplatin in the Male Germline Cells of Swiss Mice

Pages 352-359 | Published online: 18 Jul 2013
 

Abstract

Cisplatin (CP) (in Oncoplatin), a widely used drug in cancer chemotherapy, and cyclophosphamide (CY) (in Endoxan), another anticancer drug, were investigated as the test chemical and positive control, respectively, for their cytogenetic effects on spermatogonia of mice at 24 hours post-treatment after a single exposure. The different doses of the chemicals tested were CP 2, 3, 5 mg/kg and CY 40 mg/kg b.w. of mice. Each of the doses of CP induced a significant number of chromosomal aberrations, mostly chromatid breaks and fragments. The potential transmission of such cytogenetic effects of the chemicals from spermatogonia to spermatocytes was assessed at week 4 post-treatment from the primary spermatocytes, which showed a significant number of aberrant spermatocytes with atypical bivalents viz. spermatocytes with autoso-mal and/or XY univalents, tetravalents and with extra elements. The probable causes of the formation of univalents and tetravalents are discussed. The transmission of the cytogenetic effects of the chemicals from spermatogonia up to sperm was assessed at week 8 post-treatment from the morphology of sperm collected from vas. Quantitatively the transmission of such effects was found decreased substantially by the time the exposed spermatogonia became sperm. Still there was the occurrence of a few abnormal sperm at week 8 post-treatment. The probable causes of the quantitative decrease in the transmission of the effects from spermtogonia to sperm are discussed.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.